Upgrades In-line Outperform X

CRSP CRISPR Therapeutics

Evercore ISI

$60 $99

Upgrades Sell Hold X

CRSP CRISPR Therapeutics

TD Cowen

$35

Initiated Buy X

CRSP CRISPR Therapeutics

H.C. Wainwright

$65

Reiterated Buy X

CRSP CRISPR Therapeutics

Needham

$88 $84

Resumed Neutral X

CRSP CRISPR Therapeutics

Guggenheim

Initiated Peer Perform X

CRSP CRISPR Therapeutics

Wolfe Research

Downgrades Mkt Perform Underperform X

CRSP CRISPR Therapeutics

TD Cowen

$30

Initiated Buy X

CRSP CRISPR Therapeutics

Mizuho

$82

Upgrades Neutral Buy X

CRSP CRISPR Therapeutics

Citigroup

Initiated Outperform X

CRSP CRISPR Therapeutics

William Blair

$75

Initiated Overweight X

CRSP CRISPR Therapeutics

Cantor Fitzgerald

$72

Initiated Mkt Perform X

CRSP CRISPR Therapeutics

Bernstein

$44

Initiated Buy X

CRSP CRISPR Therapeutics

Bryan Garnier

$70

Initiated Neutral X

CRSP CRISPR Therapeutics

Robert W. Baird

$46

Initiated Underweight X

CRSP CRISPR Therapeutics

Morgan Stanley

$37

Downgrades Overweight Eq Weight X

CRSP CRISPR Therapeutics

Barclays

$99 $88

Downgrades Outperform In-line X

CRSP CRISPR Therapeutics

Evercore ISI

$66 $60

Initiated Outperform X

CRSP CRISPR Therapeutics

BMO Capital Markets

$98

Initiated Neutral X

CRSP CRISPR Therapeutics

Credit Suisse

$78

Initiated Market Perform X

CRSP CRISPR Therapeutics

Cowen

Initiated Outperform X

CRSP CRISPR Therapeutics

SVB Leerink

$126

Upgrades Sell Neutral X

CRSP CRISPR Therapeutics

Citigroup

$55 $132

Upgrades Hold Buy X

CRSP CRISPR Therapeutics

Jefferies

$172

Initiated Mkt Outperform X

CRSP CRISPR Therapeutics

JMP Securities

$160

Initiated Buy X

CRSP CRISPR Therapeutics

Jefferies

$64

Initiated Buy X

CRSP CRISPR Therapeutics

Canaccord Genuity

$72

Initiated Buy X

CRSP CRISPR Therapeutics

ROTH Capital

$50

Initiated Outperform X

CRSP CRISPR Therapeutics

Evercore ISI

Initiated Mkt Perform X

CRSP CRISPR Therapeutics

William Blair

Downgrades Buy Neutral X

CRSP CRISPR Therapeutics

Goldman

Downgrades Neutral Sell X

CRSP CRISPR Therapeutics

Citigroup

Initiated Buy X

CRSP CRISPR Therapeutics

Needham

$62

Initiated Neutral X

CRSP CRISPR Therapeutics

Guggenheim

Initiated Outperform X

CRSP CRISPR Therapeutics

Wells Fargo

$65

Initiated Underperform X

CRSP CRISPR Therapeutics

Raymond James

Reiterated Buy X

CRSP CRISPR Therapeutics

Chardan Capital Markets

$25 $72.50

Initiated Buy X

CRSP CRISPR Therapeutics

Goldman

$86

Initiated Mkt Outperform X

CRSP CRISPR Therapeutics

JMP Securities

$69

CRSP  CRISPR Therapeutics AG

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.